Regulation of CD45-induced signaling by galectin-1 in Burkitt lymphoma B cells

被引:68
|
作者
Fouillit, M
Joubert-Caron, R
Poirier, F
Bourin, P
Monostori, E
Levi-Strauss, M
Raphael, M
Bladier, D
Caron, M
机构
[1] Univ Paris 13, URF Leonard De Vinci, Lab Biochim Prot & Proteom, F-93017 Bobigny, France
[2] Ctr Transfus Sanguine, Lab Immunol Cellulaire, F-92140 Clamart, France
[3] Inst Genet, Biol Res Ctr, H-6726 Szeged, Hungary
[4] Hop Necker Enfants Malad, INSERM U 25, F-75015 Paris, France
关键词
Burkitt lymphoma; CD45; cell death; galectin; Lyn;
D O I
10.1093/glycob/10.4.413
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It has been well established that Galectin-1 (GAL1), a beta-galactoside-binding protein, regulates the viability of lymphoid cells. However, the signaling pathway governed by the binding of GAL1 to the cell membrane is not understood. As a first step towards the elucidation of GAL1-initiated signaling events leading to a reduced viability of Burkitt lymphoma B cells, we tried to characterize the initial events induced by the binding of GAL1 to its receptor. This characterization was performed in BL36 cells, a Burkitt lymphoma cell line sensitive to GAL1, The results were as follows: (1) when solubilized cell membrane lysates were affinity bound to immobilized GAL1 and eluted by competition, the tyrosine phosphatase glycoprotein CD45 was found in the eluate, highlighting the role of CD45 as a receptor of GAL1; (2) the phosphatase activity of cell membranes diminished after incubation with GAL1; (3) immunoprecipitation experiments demonstrated that the phosphotyrosine kinase Lyn was dysregulated in cells that have been cultured in medium containing 700 nM GAL1, and (4) that the ratio between two isoforms of Lyn was modified during the treatment with GAL1. The regulation of Lyn therefore seems to be a key event in the action of GAL1.
引用
收藏
页码:413 / 419
页数:7
相关论文
共 50 条
  • [1] CD45 Phosphatase Domain Required For Regulation Of Galectin-1 Induced T cell Death
    Earl, Lesley
    Bi, Shuguang
    Baum, Linda G.
    FASEB JOURNAL, 2008, 22
  • [2] Galectin-1 expression in Hodgkin-lymphoma cells
    Mark, A.
    Hajdu, M.
    Nemes, K.
    Sticz, T.
    Krenacs, T.
    Kopper, L.
    Sebestyen, A.
    EJC SUPPLEMENTS, 2010, 8 (05): : 142 - 143
  • [3] Involvement of CD2 and CD3 in galectin-1 induced signaling in human Jurkat T-cells
    Walzel, H
    Blach, M
    Hirabayashi, J
    Kasai, K
    Brock, J
    GLYCOBIOLOGY, 2000, 10 (02) : 131 - 140
  • [4] Galectin-1 supports the survival of CD45RA(-) primary myeloma cells in vitro
    Abroun, Saeid
    Otsuyama, Ken-Ichiro
    Shamsasenjan, Karim
    Islam, Abul
    Amin, Jakia
    Iqbal, Mohd S.
    Gondo, Toshikazu
    Asaoku, Hideki
    Kawano, Michio M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (05) : 754 - 765
  • [5] Galectin-1:: a key effector of regulation mediated by CD4+CD25+ T cells
    Garin, Marina I.
    Chu, Chung-Ching
    Golshayan, Dela
    Cernuda-Morollon, Eva
    Wait, Robin
    Lechler, Robert I.
    BLOOD, 2007, 109 (05) : 2058 - 2065
  • [6] Galectin-1 is required for the regulatory function of B cells
    R. Alhabbab
    P. Blair
    L. A. Smyth
    K. Ratnasothy
    Q. Peng
    A. Moreau
    R. Lechler
    R. Elgueta
    G. Lombardi
    Scientific Reports, 8
  • [7] Galectin-1 is required for the regulatory function of B cells
    Alhabbab, R.
    Blair, P.
    Smyth, L. A.
    Ratnasothy, K.
    Peng, Q.
    Moreau, A.
    Lechler, R.
    Elgueta, R.
    Lombardi, G.
    SCIENTIFIC REPORTS, 2018, 8
  • [8] Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells
    He, Xiaocui
    Klaesener, Kathrin
    Iype, Joseena M.
    Becker, Martin
    Maity, Palash C.
    Cavallari, Marco
    Nielsen, Peter J.
    Yang, Jianying
    Reth, Michael
    EMBO JOURNAL, 2018, 37 (11):
  • [9] Galectin-1: biphasic growth regulation of Leydig tumor cells
    Biron, Veronica A.
    Iglesias, M. Mercedes
    Troncoso, Maria F.
    Besio-Moreno, Marcos
    Patrignani, Zoraida J.
    Pignataro, Omar P.
    Wolfenstein-Todel, Carlota
    GLYCOBIOLOGY, 2006, 16 (09) : 810 - 821
  • [10] Lymphoma Galectin-1 Expression Drives CD20 Immunotherapy Resistance
    Lykken, Jacquelyn M.
    Horikawa, Mayuka
    Minard-Colin, Veronique
    Kamata, Masahiro
    Miyagaki, Tomomitsu
    Poe, Jonathan C.
    Tedder, Thomas F.
    JOURNAL OF IMMUNOLOGY, 2016, 196